Index

Adolescence: depression, suicide and deliberate self-harm in, 47–60
Aetiology of depression, and culture, 38–9
Amantadine, 95
Amitriptyline, 90, 92, 164, 166, 170, 175, 202
Amitripyline, 153
Amoxapine, 90, 168
Anderson IM: Meta-analytical studies on new antidepressants, 161–78
Anticonvulsants as mood stabilisers, 181–7
Antidepressants (ADs), 164–5
  AD2 – 2nd generation ADs, 165, 167, 170
  medication (ADM), 103–12
  mode of withdrawal from, 151–2
  new, meta-analytical studies on, 161–78
  and sexual dysfunction, 86–94
  and suicide, 174–5
Antipsychotics, 187
Anxiety and depression overlap, 38
Araya R *see* **Lewis G**
Arizona Sexual Experience Scale (ASEX), 95

Baldwin DS: Depression and sexual dysfunction, 81–99
Barkham M, Hardy GE Counselling and interpersonal therapies for depression: towards securing an evidence-base, 115–32
Beck Depression Inventory (BDI), 104, 117–21, 125–6, 129
Beck Hopelessness Scale (BHS), 139
Beck's cognitive theory of depression, 101–2
Beck's depressive cognitive triad, 18–19
Behavioural family therapy, 102
Bipolar affective disorder, 179–90, 187
Brain-derived neurotrophic factor (BDNF), 67, 69–77
British Association
  for Behavioural and Cognitive Psychotherapies (BABCP), 119
  for Psychopharmacology (BAP), 197
  of Counselling (BAC), 115, 117
Bupropion, 86, 89, 92, 94
Buspirone, 89, 95

CA3 hippocampal neurones, 72–4
cAMP response element binding protein (CREB), 64–72
Carbamazepine , 179, 181–2, 183, 185–6, 188
Childhood Experience of Care and Abuse (CECA), 21
Chinese Health Questionnaire, 36
CISR *see* Revised clinical interview schedule (CISR)
Citalopram, 91, 169
Classification of depression, 37–8
Classification, disability and the public health agenda: **Lewis G, Araya R**, 3–15
Clinical management (CM), 103-12
Clomipramine, 87, 88, 90, 202
Co-morbidity, 5
Cochrane Review, 115–17
Cognitive behavioural therapy (CBT)), 24–5, 115–32, 136–8, 139, 141, 153–55
  model, 135
  treatment programmes, 52
Cognitive therapy for depression: **Scott J**, 101–13
Composite International Diagnostic Interview (CIDI), 6, 37
Computer-based and written self-help treatments for depression, 133–44
Consultations (professional) for common mental disorder, lay attitudes to, 207–19
Continuation and maintenance therapy in depression: **Paykel ES**, 145–59
COPE system, for self-help, 137
Counselling and interpersonal therapies for depression: towards securing an evidence-base: **Barkham M, Hardy GE**, 115–32
Cross-cultural psychiatry, the relevance of: a critique, 34–5
Cultural factors and international epidemiology: **Patel V**, 33–45
Cut-off scores for caseness, 36
Cyproheptadine, 95

© The British Council 2001

Deliberate self-harm (DSH), 54–8
Dentate gyrus (DG), 74–5
Depression and
– emerging insights from neurobiology: **Vaidya VA, Duman RS**, 61–70
public health, 12–13
sexual dysfunction: **Baldwin DS**, 81–99
suicide and deliberate self-harm in adolescence: **Harrington RC**, 47–60
Desipramine, 87, 202
Developments in mood stabilisers: **Ferrier IN**, 179–92
Dexamethasone Suppression Test (DST), 104
Dexamphetamine, 95
Diagnosis of depression, 35–8
Diagnostic and Statistical Manual of Mental Disorders
(DSM-III), 10, 83
(DSM-IV), 4, 48, 82–83, 195
Differential diagnosis of other difficulties, 48–9
Disability Adjusted Life Years (DALYs), 7–9
Disability, classification, and the public health agenda, 3–15
Dothiepin, 170, 202
Doxepin, 87, 92
Duman RS see **Vaidya VA**
Dysfunctional Attitudes Scale (DAS), 139

Effect size (ES), 118, 120, 121, 125, 169
Effectiveness of computer-administered self-help materials, 136–8
Effectiveness of written self-help materials, 135–6
Elderly patients and new antidepressants, 174
Electroconvulsive seizure (ECS), 74–5
Electroconvulsive therapy (ECT), 148, 149, 187–8
in adolescents, 53
Endogenous depression, 20–1
Epidemiological Catchment Area Study, 9–10
Epidemiology
(international), cultural factors and, 33–45
and sexual dysfunction, 83-4
Evidence-base, towards securing an: counselling and interpersonal therapies for depression, 115–32

Ferrier IN: Developments in mood stabilisers, 179–92
Fluoxetine, 53, 87, 88, 90–2, 94, 148, 161, 164, 169, 171, 172, 175, 202
Fluvoxamine, 89, 90, 91, 169–71, 175
Fresh start experiences and remission from depression, 19

G-protein receptor, 63
Gabapentin, 184
Gender and culture on depression, 38–9
Gene modification and depression, 66–72
General Health Questionnaire (GHQ), 36, 139
Global burden of disease (GBD), 8
Guidelines in primary care, treatment delivery and, 193–206

Hamilton Rating Scales for Depression (HAMD), 5, 88, 104, 194
Hampshire Depression Project, 198–200
Hardy GE *see* **Barkham M**
Harrington RC: Depression, suicide and deliberate self-harm in adolescence, 47–60
Harris TO: Recent developments in understanding the psychosocial aspects of depression, 17–32
Health Action Zones, 25
Health Technology Assessment (HTA) programme, 117
Hippocampal CA3, 72–4
Humiliation/entrapment (H/E) and depressive onset, 18–20

Imipramine, 53, 87, 90, 150, 164, 170, 202
Indian Psychiatric Survey Schedule, 37
Inducible cAMP early repressor (ICER) proteins, 69
Interactive voice response (IVR) system, 137
International Classification of Mental and Behavioural Disorders (ICD), 34
ICD-10 (diagnostic manual), 4, 82
International Pathways to Care Study, 39
Interpersonal psychotherapy (IPT), 24, 102, 105, 123, 125, 127, 152–3, 154
Interpersonal therapies and counselling for depression: towards securing an evidence-base, 115–32
Ischaemic heart disease (IHD), 9

Kendrick T *see* Peveler R

Lader MH, Cowen PJ: Preface, 1–2
Lamotrigine, 179, 181, 183–4, 185–6
Lay attitudes to professional consultations for common mental disorder: a sociological perspective: **Pill R, Prior L, Wood F**, 207–19
Lay attitudes to professional consultations for common mental disorder, 207–19
Lewis G, Araya R: Classification, disability and the public health agenda, 3–15
Life Events, 10
and Difficulties Schedule (LEDS). 11
Lithium, 148, 151, 179–81
Lithium-tricyclic combinations, 151
Lofepramine, 164, 165, 167–8, 175, 202

Maintenance and continuation therapy in depression, 145–59
Management of depression, and culture, 39
Maprotiline, 164, 165, 170, 202
Mediators of effect, 110
Messenger cascades, regulation of intracellular, 62–66
Meta-analytical studies on new antidepressants: **Anderson IM**, 161–78
Methods for assessing depressive disorders, 5–7
Mianserin, 95, 170, 202
Milnacipran, 88, 149, 166
Mirtazapine, 86, 88, 89, 92, 94, 164, 166, 172–3, 175
Moclobemide, 86–88, 90, 92, 175
Monoamine oxidase inhibitors (MAOIs) as antidepressants, 86, 94, 145, 147–9, 151
Mood stabilisers
developments in, 151, 179–92
issues relating to prescribing anticonvulsants, 185–7

National Institute of Mental Health (NIMH) Treatment of Depression Collaborative Research Program, 101, 103, 104, 106, 109
Nefazodone, 86, 90, 92, 93, 165, 169, 182
Neostigmine, 95
Neurobiology, depression – emerging insights from, 61–70
Neurotoxicity with lithium, 180

Newer antidepressants (NA), 166, 167
elderly patients and, 174
Non-directive counselling (NDC), 119–20
Nortriptyline, 53, 87, 202
Number needed to harm (NNH), 162
Number needed to treat (NNT), 162, 163, 169, 173

Odds ratio (OR), 162, 167, 171
Older antidrepressants (OA), 164, 165, 166, 167
OPCS National Survey of Psychiatric Morbidity. 6,12, 210
Outcome research, 103–8
of continuation and maintainence therapy, 145–7
Overcoming depression course, 141–3

Paroxetine, 87, 90, 91, 92, 169
Patel V: Cultural factors and international epidemiology, 33–45
Paykel ES: Continuation and maintenance therapy in depression, 145–59
Peveler R, Kendrick T: Treatment delivery and guidelines in primary care, 193–206
Phenelzine, 90
Phosphodiesterases (PDEs), 64
Pill R, Prior L, Wood F: Lay attitudes to professional consultations for common mental disorder: a sociological perspective, 207–19
Predictors of response, 108–10
Preface: **Lader MH, Cowen PJ,** 1–2
Primary care guidelines, treatment delivery and, 193–206
Primary Care Psychiatric Questionnaire (PPQ), 36
Prior L *see* **Pill R**
Psycho-education and psychological treatments, 188
Psychodynamic-interpersonal therapy (PDIPT), 123–5, 127–9
Psychosocial aspects of depression, recent developments in understanding the, 17–32
Psychosocial interventions, 52–3
Public health agenda, classification and disability, 3–15

Randomised control trials (RCTs), 147, 161, 164, 167, 175, 181, 182, 184

Rapid Eye Movement (REM) sleep latency, 104
Rebound phenomena, 186
Reboxetine, 86
Recent developments in understanding the psychosocial aspects of depression: **Harris TO**, 17–32
Receptor activation, 64
Relative effect size (ES), 162
Reversible inhibitors of monoamine oxidase A (RIMAs), 165, 168–9, 174, 175
Revised Clinical Interview Schedule (CISR), 6, 12, 37, 210
Risk difference (RD), 162, 163, 169
Risk ratio (RR), 162, 163, 169

Schedules for Clinical Assessment in Neuropsychiatry (SCAN), 5–6, 37
Scott J: Cognitive therapy for depression, 101–13
Screening questionnaires, 36–7
Second Sheffield Psychotherapy Project (SPP2), 122, 123–7, 129
Self Reporting Questionnaire (SRQ), 36
Self-harm (deliberate), depression, and suicide in adolescence, 47–60
Self-help treatments for depression, written and computer-based 133–44
Serotonin and noradrenaline re-uptake inhibitors (SNRIs), 161, 164, 168, 172–4, 176
Serotonin specific re-uptake inhibitors (SSRIs), 53, 86, 88–90, 94, 95, 147, 149, 151, 161, 164–7, 169–72, 182, 202
Sertraline, 89–93, 169, 171, 175
Sexual dysfunction,
  depression and, 81–99
  methods of assessing, 94–5
  treatment, 95–6
Sexual Function Questionnaire, 89, 95
Shona Symptom Questionnaire in Zimbabwe, 36
Short-term psychodynamic psychotherapy (STPDT), 123
Sildenafil (Viagra), 81, 95–6
Social Adjustment Scale, 88
Social capital, 20
Socio-economic status and depression, 11–12
Sociological perspective: lay attitudes to professional consultations for common mental disorder, 207–19
St John's wort, 166
Stigma of depression – a personal view: **Wolpert L**, 221–4
Structural plasticity and depression, 72–6
Suicide
  and antidepressants, 174–5
  depression and deliberate self-harm in adolescence, 47–60
  rate, effects on, 187
Sure Start, 25

TCAs, 199
Teratogenesis, 186
Thyroid hormones and bipolar disorder, 188
Tiagabine, 184
Topiramate, 184
Transcranial magnetic stimulation (TMS), 188
Trazodone, 87, 170, 202
Treatment delivery and guidelines in primary care: **Peveler R, Kendrick T**, 193–206
Tricyclic antidepressants (TCAs), 53, 86, 88, 90, 94, 145, 147, 149, 150–1, 161, 163–5, 169–74
  (TCA2) – 2nd generation, 167

Vaidya VA, Duman RS: Depression – emerging insights from neurobiology, 61–70
Valproate semi-sodium ('Depakote'), 181
Valproate, 179, 181, 182–3, 185–6, 188
Venlafaxine, 87, 88, 90, 92, 166, 169

Whitfield G *see* **Williams C**
Williams C, Whitfield G: Written and computer-based self-help treatments for depression, 133–44
Wolpert L: Stigma of depression – a personal view, 221–4
Wood F see **Pill R**
Written and computer-based self-help treatments for depression: **Williams C, Whitfield G**, 133–44

Yohimbine, 95